Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Sök Study Connect
  • NCT07415031

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies - CA239-0071

Uppdaterad: 13 maj, 2026   |   ClinicalTrials.gov

Utskriftsvänlig sammanfattning

ÄR DU INTRESSERAD AV DEN HÄR PRÖVNINGEN?
Skriv ut den här sidan och broschyren om kliniska prövningar som hjälp under samtalet med din läkare.
Använd broschyren ”Om att delta i en klinisk prövning” för att få vägledning om deltagandeprocessen i en klinisk prövning. Förstå de viktiga faktorerna som man måste tänka på före ett beslut och få hjälp med att formulera frågor till studiepersonalen.
Skriv ut den här sidan CA239-0071
Ladda ned broschyren ”Om att delta i en klinisk prövning”

VÄLJ SPRÅK

Information om prövningen

  • Phase 2

    Fas

  • Kön

  • 18+

    Åldersintervall

  • 45

    Platser

  • Recruiting

Behandlingsalternativ

Studiegrupper
TILLDELAD BEHANDLING
Experimental: Arm A1
Drug: Adagrasib
Experimental: Arm A2
Drug: Adagrasib
Experimental: Arm B1
Drug: Adagrasib, Pembrolizumab
Experimental: Arm B2
Drug: Adagrasib, Pembrolizumab
Experimental: Arm B3
Drug: Adagrasib, Cetuximab
Experimental: Arm B4
Drug: Adagrasib, Pembrolizumab, Pemetrexed
Experimental: Arm C1
Drug: Pembrolizumab
Experimental: Arm C2
Drug: Docetaxel
Experimental: Arm C3
Drug: Irinotecan, Leucovorin, Fluorouracil
Experimental: Arm C4
Drug: Leucovorin, Oxaliplatin, Fluorouracil

Viktiga kriterier för deltagandet

Inclusion Criteria: - Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. - Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: - Participant is not eligible for study treatment per the parent study eligibility criteria. - Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. - Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.

Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information

466-SE-2100058